Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TNKS2 | Q9H2K2 | 15/20 | 1.00 |
| ▸ | PARP15 | Q460N3 | 14/20 | 1.00 |
| ▸ | PARP10 | Q53GL7 | 13/20 | 1.00 |
| ▸ | PARP2 | Q9UGN5 | 14/20 | 0.66 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | BRPF1 | P55201 | 1/20 | 0.43 |
| ▸ | PARP14 | Q460N5 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25325363 | 0.78 | PARP2 (1.00) | TNKS2PARP15PARP10PARP2KDM4E | |
| SCHEMBL25323203 | 0.78 | TNKS2 (1.00) | TNKS2PARP15PARP10PARP2KDM4E | |
| SCHEMBL11743573 | 0.76 | TNKS2 (1.00) | TNKS2PARP15PARP10PARP2BRPF1 | |
| SCHEMBL25326183 | 0.70 | TNKS2 (1.00) | TNKS2PARP15PARP10PARP2BRPF1 | |
| SCHEMBL11651246 | 0.70 | PARP15 (0.54) | TNKS2PARP15PARP10PARP2KDM4E | |
| SCHEMBL11652662 | 0.70 | PARP15 (0.54) | TNKS2PARP15PARP10PARP2KDM4E | |
| SCHEMBL11651046 | 0.69 | PARP15 (0.52) | TNKS2PARP15PARP10PARP2KDM4E | |
| SCHEMBL31248569 | 0.68 | TNKS2 (1.00) | TNKS2PARP15PARP10PARP2BRPF1 | |
| SCHEMBL2489012 | 0.68 | TNKS2 (1.00) | TNKS2PARP15PARP10PARP2BRPF1 | |
| SCHEMBL11652666 | 0.68 | PARP15 (0.51) | TNKS2PARP15PARP10PARP2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250177359-A1 | COMPOUNDS FOR USE IN THE TREATMENT OF CANCER AND INFLAMMATORY CONDITIONS | OULUN YLIOPISTO (FI) | 2025-06-05 | — | — | US | disclosed |
| EP-4469046-A1 | COMPOUNDS FOR USE IN THE TREATMENT OF CANCER AND INFLAMMATORY CONDITIONS | Oulun Yliopisto (FI) | 2024-12-04 | — | — | EP | disclosed |
| WO-2023144450-A1 | COMPOUNDS FOR USE IN THE TREATMENT OF CANCER AND INFLAMMATORY CONDITIONS | OULUN YLIOPISTO (FI) | 2023-08-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250177359-A1 | COMPOUNDS FOR USE IN THE TREATMENT OF CANCER AND INFLAMMATORY CONDITIONS | NAMPT, NADK, NQO1 | TNKS2 29/4885PARP15 9/4885PARP10 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.